Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 27;7(4):132. doi: 10.3390/vaccines7040132

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Serum neutralizing antibody responses to mRNA-LNP formulations in mice (adapted from reference [41]). (A) shows rabies virus neutralizing antibody titers (VNT) measured in serum of Balb/c mice three weeks after the second of two intradermal vaccinations given 3 weeks apart; vaccinations consisted of 0.05, 0.5, or 5 μg mRNA-LNP or 40 μg nonformulated mRNA or buffer. (B) shows VNT titers measured in serum of Balb/c mice two weeks after the mice received a booster dose of the same vaccine five months after the primary doses. Groups of ten mice were in each case. Dashed line shows WHO protective value (0.5 IU/mL), **** = p < 0.0001; Lipid nanoparticle (LNP)-formulated mRNA was generated using LNPs provided by Acuitas Therapeutics (Canada).